查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579433

双胍类药物市场：按类型、药物类别、剂型、分销管道划分 - 全球预测 2025-2030

Biguanides Market by Type (Finformin, Metformin), Drug Class (Branded, Generic), Dosage Form, Formulation, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年双胍类药物市场价值为52.4亿美元，预计到2024年将达到55.1亿美元，复合年增长率为5.37%，到2030年将达到75.7亿美元。

双胍类药物主要应用于医学领域，重点关注具有双胍官能基的化合物，特别是Metformin，它是2型糖尿病的主要治疗药物。该市场的范围超出了糖尿病治疗，在体重管理和卵巢综合症（PCOS）治疗方面具有潜在的应用，并且这种需求已在各种治疗领域得到证实。双胍类药物改善新陈代谢的特性正在促进其在製药和医疗保健等最终用途领域的效用，同时由于其潜在的长寿作用，人们也在探索抗衰老疗法。就市场洞察而言，主要成长要素包括全球糖尿病和METABOLIC INC.盛行率上升，刺激了对含双胍药物的需求。此外，增加对医疗基础设施的投资以及药物开发持续的技术创新也正在扩大市场。一个值得注意的商机是，健康意识的增强正在推动对更安全、长期的糖尿病管理的需求，另一个是双胍类药物作为肿瘤学辅助性治疗的尚未开拓的潜力。然而，双胍类药物也存在一些潜在副作用，如乳酸性酸中毒，这需要谨慎的剂量和严格的监管障碍。此外，市场学名药已饱和状态，存在价格竞争压力。创新的赌注应集中在製剂技术的进步上，这些技术可改善给药机制并减少副作用，从而将双胍药物的范围扩大到其传统用途之外。此外，联合治疗的研究可以透过提高治疗功效来提供竞争优势。市场仍然充满活力，监管变化和专利到期都会影响竞争策略。为了实现永续成长，公司应优先考虑策略伙伴关係，并利用资料分析来客製化以患者为中心的解决方案，以满足新兴需求。保持生物技术进步和医疗保健创新的领先地位将提高您在这个不断变化的环境中的适应能力和市场渗透率。

主要市场统计
基准年[2023] 52.4亿美元
预测年份 [2024] 55.1亿美元
预测年份 [2030] 75.7亿美元
复合年增长率（%） 5.37%

市场动态：揭示快速发展的双胍类药物市场的关键市场洞察

双胍类药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 2 型糖尿病盛行率的增加增加了对双胍类药物等有效治疗方案的需求
    • 增加医疗支出和政府努力提高糖尿病药物的认识和可用性
    • 提高双胍疗效和患者依从性的配方技术进步
    • 越来越多的老年人口容易患糖尿病和相关併发症并需要标靶治疗
  • 市场限制因素
    • 双胍类药物的潜在副作用限制了患者的依从性
    • 双胍类药物的研究、开发和商业化高成本
  • 市场机会
    • 双胍类药物研发进展聚焦新型递送机制与剂型
    • 天然和植物来源双胍在食品和食品中越来越受欢迎
    • 随着医疗保健成本的增加和对文明病的认识的提高，新兴市场的机会
  • 市场挑战
    • 新替代品对医药应用中双胍类需求的影响
    • 工业中长期使用双胍类药物所引起的环境与健康问题

波特五力：驾驭双胍类药物市场的策略工具

波特的五力框架是了解双胍类药物市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解双胍类药物市场的外部影响

外部宏观环境因素对双胍类药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解双胍类药物市场竞争状况

双胍类药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵双胍类药物市场供应商的绩效评估

FPNV定位矩阵是评估双胍类药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘双胍类药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对双胍类药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 2 型糖尿病盛行率的不断上升增加了对双胍类药物等有效治疗方案的需求。
      • 不断上涨的医疗保健成本和政府努力提高糖尿病药物的认知度和可用性
      • 药物製剂技术的进步提高了双胍类药物的疗效和患者依从性。
      • 老年人口越来越容易患糖尿病和相关併发症，因此需要有标靶治疗。
    • 抑制因素
      • 双胍类药物的潜在副作用限制了患者的依从性
      • 双胍类药物的研究、开发和商业化高成本
    • 机会
      • 双胍类药物研发进展聚焦于新的递送机制和製剂
      • 天然和植物来源双胍药物在食品和食品中越来越受欢迎
      • 不断上涨的医疗保健成本和人们对文明病的认识不断提高，正在新兴市场创造商机
    • 任务
      • 新替代品对医药应用中双胍类药物需求的影响
      • 工业中长期使用双胍类药物所带来的环境与健康问题
  • 市场区隔分析
    • 类型：Metformin因其有效性、安全性和经济性而被广泛使用。
    • 分销管道：价格比较、定期药品配送的订阅服务以及购买自由增加了线上平台的参与度。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章双胍类药物市场：依类型

  • 芬福明
  • Metformin

第七章依药物类别分類的双胍类药物市场

  • 品牌
  • 非专利的

第八章双胍类药物市场（按剂型）

  • 口服液
  • 药片

第九章 处方双胍类药物市场

  • 缓释性
  • 即时发布

第10章双胍类药物市场：按分销管道划分

  • 离线
  • 在线的

第十一章 美洲双胍类药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太双胍类药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲双胍类药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Zydus 的 Zitubimet XR 片剂获得美国FDA核准
    • Lupin 收购勃林格殷格翰的两个糖尿病品牌
    • Xigduo XR在中国核准用于治疗成人第二型糖尿病
  • 战略分析和建议

公司名单

  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Co Ltd.
  • Endo International PLC
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Player Name
  • Sanofi SA
  • Servier Laboratories
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-3204321AF9EA

The Biguanides Market was valued at USD 5.24 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 5.37%, to USD 7.57 billion by 2030.

Biguanides, primarily used in the pharmaceutical sector, focus on compounds featuring the biguanide functional group, prominently Metformin, a leading treatment for type 2 diabetes. The scope of this market extends beyond diabetes care to potential applications in weight management and polycystic ovary syndrome (PCOS) treatments, showcasing its necessity across various therapeutic areas. The metabolic-improving properties of biguanides are driving their utility in end-use sectors such as pharmaceuticals and healthcare, alongside explorations in anti-aging therapies due to their potential longevity benefits. In terms of market insights, key growth influencers include the rising global incidence of diabetes and metabolic syndrome, spurring demand for biguanide-containing pharmaceuticals. Additionally, increasing investments in healthcare infrastructure and continuous innovations in drug development augment market trajectory. One notable opportunity rests in the expanding health-conscious demographic, prompting the need for safer, long-term diabetic management options, while another lies in the underexplored potential for biguanides in oncology as adjunct therapies. However, market growth encounters challenges such as the potential adverse effects of biguanides, like lactic acidosis, necessitating cautious administration and potential regulatory hurdles. Moreover, market saturation with generic versions presents competitive pricing pressure. Bets on innovation should focus on advancing formulation technologies to improve delivery mechanisms and reduce side effects, expanding the applicability of biguanides beyond conventional uses. Additionally, research into combination therapies could provide a competitive edge by offering enhanced therapeutic benefits. The market remains dynamic, driven by regulatory shifts and patent expiration timelines which influence competitive strategies. For sustained growth, companies should prioritize strategic partnerships and leverage data analytics to tailor patient-centric solutions that meet emerging needs. Keeping a keen eye on biotechnological advancements and healthcare reform can enhance adaptability and market penetration in this evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 5.24 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 7.57 billion
CAGR (%) 5.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biguanides Market

The Biguanides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of type 2 diabetes driving demand for effective treatment options like biguanides
    • Rising healthcare expenditure and government initiatives boosting awareness and accessibility of diabetes medications
    • Technological advancements in pharmaceutical formulations improving efficacy and patient compliance of biguanides
    • Growing geriatric population more susceptible to diabetes and related comorbidities necessitating targeted treatments
  • Market Restraints
    • Potential side effects of Biguanides limiting patient adherence
    • High costs associated with research, development, and commercialization of Biguanides
  • Market Opportunities
    • Advancements in biguanides research and development focused on novel delivery mechanisms and formulations
    • Growing popularity of natural and plant-based biguanides in dietary supplements and nutraceuticals
    • Opportunities in emerging markets with increasing healthcare spending and awareness of lifestyle diseases
  • Market Challenges
    • The effect of emerging alternatives on the demand for biguanides in pharmaceutical applications
    • Environmental and health concerns associated with long-term use of biguanides in industries

Porter's Five Forces: A Strategic Tool for Navigating the Biguanides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biguanides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biguanides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biguanides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biguanides Market

A detailed market share analysis in the Biguanides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biguanides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biguanides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biguanides Market

A strategic analysis of the Biguanides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biguanides Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals, Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Co Ltd., Endo International PLC, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Player Name, Sanofi S.A., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Biguanides Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Finformin and Metformin.
  • Based on Drug Class, market is studied across Branded and Generic.
  • Based on Dosage Form, market is studied across Oral Solutions and Tablets.
  • Based on Formulation, market is studied across Extended-release and Immediate-release.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of type 2 diabetes driving demand for effective treatment options like biguanides
      • 5.1.1.2. Rising healthcare expenditure and government initiatives boosting awareness and accessibility of diabetes medications
      • 5.1.1.3. Technological advancements in pharmaceutical formulations improving efficacy and patient compliance of biguanides
      • 5.1.1.4. Growing geriatric population more susceptible to diabetes and related comorbidities necessitating targeted treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential side effects of Biguanides limiting patient adherence
      • 5.1.2.2. High costs associated with research, development, and commercialization of Biguanides
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in biguanides research and development focused on novel delivery mechanisms and formulations
      • 5.1.3.2. Growing popularity of natural and plant-based biguanides in dietary supplements and nutraceuticals
      • 5.1.3.3. Opportunities in emerging markets with increasing healthcare spending and awareness of lifestyle diseases
    • 5.1.4. Challenges
      • 5.1.4.1. The effect of emerging alternatives on the demand for biguanides in pharmaceutical applications
      • 5.1.4.2. Environmental and health concerns associated with long-term use of biguanides in industries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Wide use of metformin owing to its efficacy, better safety profile, and affordability
    • 5.2.2. Distribution Channel: Increasing engagement on online platforms due to price comparison, subscription services for regular medication delivery, and purchasing discretion.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biguanides Market, by Type

  • 6.1. Introduction
  • 6.2. Finformin
  • 6.3. Metformin

7. Biguanides Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Branded
  • 7.3. Generic

8. Biguanides Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Oral Solutions
  • 8.3. Tablets

9. Biguanides Market, by Formulation

  • 9.1. Introduction
  • 9.2. Extended-release
  • 9.3. Immediate-release

10. Biguanides Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
  • 10.3. Online

11. Americas Biguanides Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Biguanides Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Biguanides Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Zydus receives USFDA approval for Zituvimet XR tablets
    • 14.3.2. Lupin acquires two diabetes brands from Boehringer Ingelheim
    • 14.3.3. Xigduo XR approved in China for adults with type-2 diabetes
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amneal Pharmaceuticals, Inc.
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Bayer AG
  • 5. Biocon Limited
  • 6. Boehringer Ingelheim International GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Limited
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Co Ltd.
  • 11. Endo International PLC
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Ltd.
  • 14. Hikma Pharmaceuticals PLC
  • 15. Lupin Pharmaceuticals, Inc.
  • 16. Mallinckrodt Pharmaceuticals
  • 17. Merck & Co., Inc.
  • 18. Mylan N.V.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Player Name
  • 22. Sanofi S.A.
  • 23. Servier Laboratories
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.
  • 26. Torrent Pharmaceuticals Ltd.
  • 27. Wockhardt Ltd.
  • 28. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. BIGUANIDES MARKET RESEARCH PROCESS
  • FIGURE 2. BIGUANIDES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIGUANIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIGUANIDES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIGUANIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIGUANIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIGUANIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIGUANIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIGUANIDES MARKET SIZE, BY FINFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIGUANIDES MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIGUANIDES MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIGUANIDES MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIGUANIDES MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIGUANIDES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIGUANIDES MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIGUANIDES MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIGUANIDES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIGUANIDES MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. THAILAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. VIETNAM BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. DENMARK BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EGYPT BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. FINLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. FRANCE BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. GERMANY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. ISRAEL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. ITALY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. NETHERLANDS BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. NIGERIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NORWAY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. POLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. QATAR BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. RUSSIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SPAIN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SWEDEN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SWITZERLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. TURKEY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. BIGUANIDES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 232. BIGUANIDES MARKET, FPNV POSITIONING MATRIX, 2023